Pharmaceutico-analytical study and randomized controlled clinical trial of modified mukhakantiprada lepa in vyanga

Sane guruji Arogya kendra1 个研究点分布在 1 个国家目标入组 60 人开始时间: 2019年1月6日最近更新: 2019年5月26日

试验速览

阶段: 不适用
状态: 尚未招募
发起方: Sane guruji Arogya kendra
入组人数: 60
试验地点: 1
主要终点: 1. Colour of lesion(patch)

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

There are two groups in this study with 30 patients in each group, Group A will be treated with mukhkantiprada lepa and group B will be treated with Modified form of lepa as a cream. Patients will be selected for group through generated randomized number chart.Drugs for both group will be given for 30 days with follow up on 15th and 30th day of the trial.

Size of lesion,colour of lesion and number of patches will be recorded on first and follow up days.

Mukhkantiprada lepa ia mentioned by ahranghshr in vyanga but due to day today life style,shelf life of drugs,lack of time it ia difficult to use kela by people.As mukhkantiprada cream(novel dosage form)will be used as alternative source of drug.

研究设计

研究类型: Interventional
分配方式: Computer generated randomization
盲法: Participant Blinded

入排标准

年龄范围: 20.00 Year(s) 至 50.00 Year(s)（—）
性别: All

入选标准

•1.Patient showing signs and symptoms of vyanga as per classical text like Niruja(painless),Mandala(round patch),Shyava(blotchy brown pigmentation) on face.

排除标准

•1.Birth mark 2.Any known facial injuries with scares 3.Hormonal therapy and patient with systemic disorders.
•4.Patients on any other medication for the same problem during the study 5.Pregnant ladies.

结局指标

主要结局

1. Colour of lesion(patch)

时间窗: 30 days

次要结局

1.Number of lesions(patch)(2.Size of lesion(patch))

研究者

发起方

Sane guruji Arogya kendra

申办方类型

Private hospital/clinic

研究点 (1)

Loading locations...

相似试验

已完成

3 期

A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)Osteoarthritis

NCT00092352Merck Sharp & Dohme LLC395

已完成

3 期

A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)Osteoarthritis

NCT00092365Merck Sharp & Dohme LLC413

尚未招募

4 期

STUDY THE EFFECT OF VELVET LEAF POWDER IN DIARRHOEA

CTRI/2022/07/044303Yashwant Ayurvedic Medical College Kodoli kolhapur Maharashtra100

已完成

1 期

Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM®Healthy

NCT01320410Rovi Pharmaceuticals Laboratories

Unknown

不适用

Efficacy and Safety of Plasma Exchange Compared to Standard Medical Therapy in Patients With Severe Drug Induced Liver Injury With or Without Underlying Chronic Liver Disease.Chronic Liver Disease

NCT04015570Institute of Liver and Biliary Sciences, India30